pembrolizumab + trastuzumab + fluoropyrimidine + platinum chemotherapy

ERBB2 Amplification, +1 more biomarker

Adenocarcinoma of the Gastroesophageal Junction, +1 more condition

Locally advanced, +2 more states

First line

fluoropyrimidine, +3 more drugs

chemotherapy, +2 more types

fam-trastuzumab deruxtecan

ERBB2 Amplification, +1 more biomarker

Adenocarcinoma of the Gastroesophageal Junction, +1 more condition

Locally advanced, +1 more state

Subsequent line

fam-trastuzumab deruxtecan

targeted therapy

margetuximab + chemotherapy

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

Metastatic

Subsequent line

chemotherapy, +1 more drug

chemotherapy, +1 more type

pertuzumab/trastuzumab/hyaluronidase + chemotherapy

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

Early stage, +1 more state

Neoadjuvant

chemotherapy, +1 more drug

chemotherapy, +1 more type

pertuzumab/trastuzumab/hyaluronidase + chemotherapy

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

Early stage

Adjuvant

chemotherapy, +1 more drug

chemotherapy, +1 more type

pertuzumab/trastuzumab/hyaluronidase + docetaxel

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

Metastatic

First line

docetaxel, +1 more drug

chemotherapy, +1 more type

trastuzumab + tucatinib + capecitabine

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

Advanced, +2 more states

Subsequent line

capecitabine, +2 more drugs

chemotherapy, +1 more type

neratinib + capecitabine

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

Advanced, +1 more state

Subsequent line

capecitabine, +1 more drug

chemotherapy, +1 more type

fam-trastuzumab deruxtecan

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

Metastatic, +1 more state

Subsequent line

fam-trastuzumab deruxtecan

targeted therapy

ado-trastuzumab emtansine

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

Early stage

Adjuvant

ado-trastuzumab emtansine

targeted therapy

trastuzumab/hyaluronidase

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

Metastatic

Subsequent line

trastuzumab/hyaluronidase

targeted therapy

trastuzumab/hyaluronidase

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

Adjuvant

trastuzumab/hyaluronidase

targeted therapy